Novartis enters a licensing agreement with China-based Abogen Biosciences worth up to $7.8 billion, paying $575 million upfront for global rights to an early-stage mRNA autoimmune therapy. This deal highlights a growing trend of Western drugmakers turning to Chinese biotechs to replenish their pipelines ahead of a major patent cliff in the early 2030s. Driven by regulatory reforms and rapid clinical trials, China is projected to account for a third of global pharmaceutical pipelines in 2026.
Novartis and Abogen licensing agreement
- ▪Under the licensing agreement between Novartis and Abogen Biosciences, Novartis will secure an exclusive option to license future assets developed on Abogen Biosciences' RNA platform
- ▪Novartis will pay Abogen Biosciences $575 million upfront for the global rights to Abogen's mRNA therapy, with an additional $7.2 billion in milestone payments, bringing the total potential value to $7.8 billion
- ▪Novartis entered a licensing agreement with China-based Abogen Biosciences for Abogen's lead asset, an early-stage experimental messenger RNA CD19xCD3 T cell engager therapy for autoimmune disease, on October 2, 2026
Novartis pipeline development
- ▪Novartis has established multiple partnership agreements with emerging Chinese biotechnology companies in recent years to strengthen its drug portfolio
- ▪Novartis' shares fell in September 2026 by the most since 1987 following several clinical trial setbacks, raising questions about its ability to develop and source new drugs
Drivers of Western interest in Chinese biopharma
- ▪Licensing deals have become the preferred method for Western drugmakers to access Chinese science, allowing them to acquire rights to experimental medicines without buying the developing companies
- ▪Ruchun Ji, a partner at Sidley, stated that licensing agreements reduce risk for Big Pharma because the licenses can be terminated if a drug fails or development priorities shift
- ▪Western biopharma companies are seeking new drug candidates in China to offset a patent cliff in the early 2030s, when patents on top-selling drugs are set to expire
- ▪For Chinese biotechnology companies, upfront and milestone payments from licensing deals provide funding while allowing them to continue drug development in their domestic market
Growth of China's biotechnology sector
- ▪ING expects the total value of Chinese biotechnology outlicensing deals to surpass $250 billion in 2026 due to rising overseas demand for Chinese drug assets
- ▪Ruchun Ji, a partner at Sidley, stated that drug innovation and clinical trials in China are highly rapid due to regulatory reforms by the National Medical Products Administration
- ▪Faster and cheaper early-stage clinical development, combined with the return of Chinese scientists trained abroad, has helped Chinese biotechs generate the data needed to attract global biopharma companies
- ▪ING estimated that China will account for approximately one-third of all new molecules in global pharmaceutical pipelines in 2026, up from 4% in 2014
Recent Chinese biotech licensing deals
- ▪AstraZeneca announced a partnership with Summit Therapeutics on October 2, 2026, to test its oncology drug Datroway in combination with Summit's ivonescimab, which was developed by Chinese biotech Akeso
- ▪GSK announced in mid-September 2026 that it was acquiring a blood cancer medicine from Chinese biotech Chimagen Biosciences for up to $750 million
- ▪Novo Nordisk announced an exclusive licensing agreement with Hengrui Pharma earlier this week for an early-stage, once-weekly GLP-1/GIP pill valued at up to $2.6 billion
Debatable claims
- ▪The rise of Chinese biotech threatens Western dominance in pharmaceutical innovation
- ▪Western drugmakers should prioritize domestic R&D over foreign licensing
Story comments
Loading comments…